1.34
-0.15 (-10.07%)
| Previous Close | 1.49 |
| Open | 1.56 |
| Volume | 5,793,013 |
| Avg. Volume (3M) | 991,293 |
| Market Cap | 195,171 |
| Price / Sales | 0.130 |
| Price / Book | 0.010 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2024 - 18 Nov 2024 |
| Operating Margin (TTM) | -13,497.11% |
| Diluted EPS (TTM) | -1,375.20 |
| Quarterly Revenue Growth (YOY) | -80.00% |
| Total Debt/Equity (MRQ) | 126.76% |
| Current Ratio (MRQ) | 0.070 |
| Operating Cash Flow (TTM) | -19.59 M |
| Levered Free Cash Flow (TTM) | -13.26 M |
| Return on Assets (TTM) | -117.61% |
| Return on Equity (TTM) | -3,493.63% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Aditxt, Inc. | Mixed | Mixed |
Stockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 0.17 |
|
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics the way bodies naturally induce tolerance to tissues. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 1.15% |
| % Held by Institutions | 1.08% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Natixis | 30 Jun 2024 | 0 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |